182 related articles for article (PubMed ID: 37232810)
1. Estimating the Burden of Illness of Relapsed Follicular Lymphoma and Marginal Zone Lymphoma in Ontario, Canada.
Kuruvilla J; Ewara EM; Elia-Pacitti J; Ng R; Eberg M; Kukaswadia A; Sharma A
Curr Oncol; 2023 Apr; 30(5):4663-4676. PubMed ID: 37232810
[TBL] [Abstract][Full Text] [Related]
2. Burden of illness of follicular lymphoma and marginal zone lymphoma.
Monga N; Nastoupil L; Garside J; Quigley J; Hudson M; O'Donovan P; Parisi L; Tapprich C; Thieblemont C
Ann Hematol; 2019 Jan; 98(1):175-183. PubMed ID: 30315345
[TBL] [Abstract][Full Text] [Related]
3. Cost-Effectiveness Analyses, Costs and Resource Use, and Health-Related Quality of Life in Patients with Follicular or Marginal Zone Lymphoma: Systematic Reviews.
Monga N; Garside J; Gurung B; Quigley J; O'Donovan P; Tapprich C; Nastoupil L; Thieblemont C; Loefgren C
Pharmacoecon Open; 2020 Dec; 4(4):575-591. PubMed ID: 32200522
[TBL] [Abstract][Full Text] [Related]
4. Real World Long-term Follow-up Experience with Yttrium-90 ibritumomab tiuxetan in Previously Untreated Patients with Low-Grade Follicular Lymphoma and Marginal Zone Lymphoma.
Alhaj Moustafa M; Peterson J; Hoppe BS; Jiang J; Wiseman GA; Witzig TE; Tun HW
Clin Lymphoma Myeloma Leuk; 2022 Aug; 22(8):618-625. PubMed ID: 35400611
[TBL] [Abstract][Full Text] [Related]
5. Phase II study of vorinostat for treatment of relapsed or refractory indolent non-Hodgkin's lymphoma and mantle cell lymphoma.
Kirschbaum M; Frankel P; Popplewell L; Zain J; Delioukina M; Pullarkat V; Matsuoka D; Pulone B; Rotter AJ; Espinoza-Delgado I; Nademanee A; Forman SJ; Gandara D; Newman E
J Clin Oncol; 2011 Mar; 29(9):1198-203. PubMed ID: 21300924
[TBL] [Abstract][Full Text] [Related]
6. Yttrium-90 Ibritumomab Tiuxetan is Cost-Effective Compared to Bendamustine + Rituximab in Low-grade Lymphomas.
Alhaj Moustafa M; Borah BJ; Moriarty JP; Dholakia R; Jiang L; Li K; Witzig TE; Hoppe BS; Peterson J; Cerhan JR; Tun HW
Clin Lymphoma Myeloma Leuk; 2023 Apr; 23(4):259-265. PubMed ID: 36775698
[TBL] [Abstract][Full Text] [Related]
7. First-line R-CVP versus R-CHOP induction immunochemotherapy for indolent lymphoma with rituximab maintenance. A multicentre, phase III randomized study by the Polish Lymphoma Research Group PLRG4.
Walewski J; Paszkiewicz-Kozik E; Michalski W; Rymkiewicz G; Szpila T; Butrym A; Giza A; Zaucha JM; Kalinka-Warzocha E; Wieczorkiewicz A; Zimowska-Curyło D; Knopińska-Posłuszny W; Tyczyńska A; Romejko-Jarosińska J; Dąbrowska-Iwanicka A; Gruszecka B; Jamrozek-Jedlińska M; Borawska A; Hołda W; Porowska A; Romanowicz A; Hellmann A; Stella-Hołowiecka B; Deptała A; Jurczak W
Br J Haematol; 2020 Mar; 188(6):898-906. PubMed ID: 31792945
[TBL] [Abstract][Full Text] [Related]
8. Long-term Follow-up of Patients with Relapsed or Refractory Non-Hodgkin Lymphoma Treated with Venetoclax in a Phase I, First-in-Human Study.
Davids MS; Roberts AW; Kenkre VP; Wierda WG; Kumar A; Kipps TJ; Boyer M; Salem AH; Pesko JC; Arzt JA; Mantas M; Kim SY; Seymour JF
Clin Cancer Res; 2021 Sep; 27(17):4690-4695. PubMed ID: 34083230
[TBL] [Abstract][Full Text] [Related]
9. Phase II study of R-CVP followed by rituximab maintenance therapy for patients with advanced marginal zone lymphoma: consortium for improving survival of lymphoma (CISL) study.
Oh SY; Kim WS; Kim JS; Kim SJ; Yoon DH; Yang DH; Lee WS; Kim HJ; Yhim HY; Jeong SH; Won JH; Lee S; Kong JH; Lim SN; Ji JH; Kwon KA; Lee GW; Lee JH; Lee HS; Shin HJ; Suh C
Cancer Commun (Lond); 2019 Oct; 39(1):58. PubMed ID: 31619290
[TBL] [Abstract][Full Text] [Related]
10. Primary follicular and marginal-zone lymphoma of the breast: clinical features, prognostic factors and outcome: a study by the International Extranodal Lymphoma Study Group.
Martinelli G; Ryan G; Seymour JF; Nassi L; Steffanoni S; Alietti A; Calabrese L; Pruneri G; Santoro L; Kuper-Hommel M; Tsang R; Zinzani PL; Taghian A; Zucca E; Cavalli F
Ann Oncol; 2009 Dec; 20(12):1993-9. PubMed ID: 19570964
[TBL] [Abstract][Full Text] [Related]
11. Long-term outcome of 487 patients with early-stage extra-nodal marginal zone lymphoma.
Teckie S; Qi S; Chelius M; Lovie S; Hsu M; Noy A; Portlock C; Yahalom J
Ann Oncol; 2017 May; 28(5):1064-1069. PubMed ID: 28327924
[TBL] [Abstract][Full Text] [Related]
12. A comprehensive retrospective cohort study of the journey of B-cell lymphoma in Taiwan.
Pei SN; Wang MC; Ma MC; Kuo CY; Liao CK; Qiu H; Rothwell LA; Liu Y
Sci Rep; 2021 May; 11(1):10069. PubMed ID: 33980914
[TBL] [Abstract][Full Text] [Related]
13. Phase II study of bortezomib in combination with rituximab, cyclophosphamide and prednisone with or without doxorubicin followed by rituximab maintenance in patients with relapsed or refractory follicular lymphoma.
Craig M; Hanna WT; Cabanillas F; Chen CS; Esseltine DL; Neuwirth R; O'Connor OA
Br J Haematol; 2014 Sep; 166(6):920-8. PubMed ID: 25039282
[TBL] [Abstract][Full Text] [Related]
14. Marginal zone B-cell lymphoma: a retrospective immunophenotypic analysis.
Kost CB; Holden JT; Mann KP
Cytometry B Clin Cytom; 2008 Sep; 74(5):282-6. PubMed ID: 18500740
[TBL] [Abstract][Full Text] [Related]
15. Relapsed or refractory nongastric marginal zone B-cell lymphoma: multicenter retrospective analysis of 92 cases.
Oh SY; Kim WS; Kim SJ; Kim JS; Kim SH; Lee DH; Won JH; Hwang IG; Kim MK; Lee SI; Kim JG; Yang DH; Kang HJ; Choi CW; Park J; Choi YJ; Kim HJ; Kwon JH; Suh C; Kim HJ
Am J Hematol; 2009 Dec; 84(12):826-9. PubMed ID: 19890833
[TBL] [Abstract][Full Text] [Related]
16. [Follicular lymphoma: first - line selection criteria of treatment].
Nesterova ES; Kravchenko SK; Kovrigina AM; Gemdzhian EG; Plastinina LV; Babaeva FE; Obukhova TN; Magomedova AU; Gaponova TV; Kremenetskaya AM; Vorobyev AI
Ter Arkh; 2019 Aug; 91(8):75-83. PubMed ID: 32598757
[TBL] [Abstract][Full Text] [Related]
17. Cutaneous b-cell lymphomas of follicular and marginal zone types: use of Bcl-6, CD10, Bcl-2, and CD21 in differential diagnosis and classification.
de Leval L; Harris NL; Longtine J; Ferry JA; Duncan LM
Am J Surg Pathol; 2001 Jun; 25(6):732-41. PubMed ID: 11395550
[TBL] [Abstract][Full Text] [Related]
18. Myeloid cell nuclear differentiation antigen is expressed in a subset of marginal zone lymphomas and is useful in the differential diagnosis with follicular lymphoma.
Metcalf RA; Monabati A; Vyas M; Roncador G; Gualco G; Bacchi CE; Younes SF; Natkunam Y; Freud AG
Hum Pathol; 2014 Aug; 45(8):1730-6. PubMed ID: 24925224
[TBL] [Abstract][Full Text] [Related]
19. Zanubrutinib monotherapy in relapsed/refractory indolent non-Hodgkin lymphoma.
Phillips T; Chan H; Tam CS; Tedeschi A; Johnston P; Oh SY; Opat S; Eom HS; Allewelt H; Stern JC; Tan Z; Novotny W; Huang J; Trotman J
Blood Adv; 2022 Jun; 6(11):3472-3479. PubMed ID: 35390135
[TBL] [Abstract][Full Text] [Related]
20. Immunoarchitectural patterns of germinal center antigens including LMO2 assist in the differential diagnosis of marginal zone lymphoma vs follicular lymphoma.
Dyhdalo KS; Lanigan C; Tubbs RR; Cook JR
Am J Clin Pathol; 2013 Aug; 140(2):149-54. PubMed ID: 23897248
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
